

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

SaOS-2

RRID:CVCL_0548

Type: Cell Line

Proper Citation

RRID:CVCL_0548

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0548

Proper Citation: RRID:CVCL_0548

Description: Cell line SaOS-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Osteosarcoma

Defining Citation: [PMID:833871](#), [PMID:2233717](#), [PMID:2823272](#), [PMID:3040234](#), [PMID:3518877](#), [PMID:6935474](#), [PMID:7017212](#), [PMID:8617485](#), [PMID:10763916](#), [PMID:11416159](#), [PMID:12645653](#), [PMID:15150091](#), [PMID:15736406](#), [PMID:15939397](#), [PMID:16888811](#), [PMID:17354236](#), [PMID:17431109](#), [PMID:17981215](#), [PMID:19787792](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21519327](#), [PMID:22075555](#), [PMID:23144859](#), [PMID:23671654](#), [PMID:24758355](#), [PMID:25031706](#), [PMID:26320182](#), [PMID:26351324](#), [PMID:27397505](#), [PMID:29334376](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SaOS-2

Synonyms: SAOS-2, Saos-2, SAOS 2, Saos 2, Saos2, SaOs2, SAOS2, Sarcoma Osteogenic-2, SaOS, SAOS

Cross References: BTO:BTO_0000971, CLO:CLO_0008947, CLO:CLO_0050140, EFO:EFO_0022402, MCCL:MCC:0000449, CLDB:cl4250, CLDB:cl4251, CLDB:cl4252, CLDB:cl5281, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-7939, ATCC:HTB-85, BCRJ:0217, BioSample:SAMN01821594, BioSample:SAMN01821661, BioSample:SAMN03471126, BioSample:SAMN10987923, cancercellines:CVCL_0548, CancerTools:161931, CCRID:1101HUM-PUMC000025, CCRID:3101HUMSCSP5057, CCRID:3101HUMTCHu114, CCRID:4201HUM-CCTCC00075, CCTCC:GDC0075, Cell_Model_Passport:SIDM01084, ChEMBL-Cells:ChEMBL3307737, ChEMBL-Targets:ChEMBL614894, CLS:300331, Cosmic:687930, Cosmic:755311, Cosmic:897500, Cosmic:909707, Cosmic:931039, Cosmic:931912, Cosmic:1044086, Cosmic:1044269, Cosmic:1070841, Cosmic:1074395, Cosmic:1082492, Cosmic:1529898, Cosmic:1733126, Cosmic:2301582, Cosmic:2816206, Cosmic-CLP:909707, DepMap:ACH-000410, DSMZ:ACC-243, DSMZCellDive:ACC-243, ECACC:89050205, EGA:EGAS00001000978, GDSC:909707, GEO:GSM170249, GEO:GSM185150, GEO:GSM185151, GEO:GSM320830, GEO:GSM827588, GEO:GSM879222, GEO:GSM1639703, GEO:GSM1639704, GEO:GSM1670401, GEO:GSM1676314, GEO:GSM1701648, GEO:GSM1915012, GEO:GSM1915013, IARC_TP53:21653, ICLC:HTL01001, IZSLER:BS TCL 90, KCB:KCB 200550YJ, KCLB:30085, KCLB:80023, LiGeA:CCLE_519, LINCS_LDP:LCL-1430, Lonza:747, NCBI_Iran:C453, PharmacDB:Saos2_1343_2019, PRIDE:PXD016398, PRIDE:PXD017130, PRIDE:PXD021564, PRIDE:PXD025970, PRIDE:PXD030304, Progenetix:CVCL_0548, PubChem_Cell_line:CVCL_0548, RCB:RCB0428, RCB:RCB3688, TKG:TKG 0469, TOKU-E:3085, Ubigene:YC-D017, Wikidata:Q7420876

ID: CVCL_0548

Record Creation Time: 20220427T221515+0000

Record Last Update: 20260829T235814+0000

Ratings and Alerts

No rating or validation information has been found for SaOS-2.

Warning: Discontinued: ATCC; CRL-7939

Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). **Warning:** Discontinued: KCLB; 80023
Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1037 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Guo L, et al. (2026) The ITGB2-COPS3-SOX2 Axis and SOX2 Liquid-Liquid Phase Separation: Dual Mechanisms Governing Osteosarcoma Stemness. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(29), e20913.

Horak I, et al. (2026) Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2-COL3A1 axis. *Molecular oncology*.

Pannese M, et al. (2026) Impaired collagen deposition in the absence of ERp44. *iScience*, 29(5), 115736.

Tao Y, et al. (2026) TENT5A Maintains MYC mRNA Stability to Enhance Osteosarcoma Stemness. *Cancer research*, 86(9), 2161.

Ross AC, et al. (2026) Modulating Galectin-1 in human osteoblast-like cells alters mineralisation and influences the expression of genes associated with osteoblasts and osteocytes. *Bioscience reports*, 46(3).

Ross AC, et al. (2026) Genes Associated With Fracture Risk in Thoroughbred Horses Have Novel Roles in Osteogenesis. *Animal genetics*, 57(4), e70166.

Wang J, et al. (2026) Prognostic characteristics of disulfidptosis-related genes across cancers and their potential implications in osteosarcoma. *Science progress*, 109(2), 368504261464856.

Nørregaard KS, et al. (2026) The Recycling Collagen Receptor uPARAP Is a Unique Mediator of Stromal Drug Delivery to Carcinoma Cells. *Molecular cancer therapeutics*, 25(1), 140.

Dias FG, et al. (2026) In Vitro Biological Evaluation of Titanium Implants Anodized With Aqueous Extract of Psidium guajava and Conventional Electrolytes. *International journal of biomaterials*, 2026, 5522753.

Zhou Y, et al. (2026) Distinct Regulation of the ARF and TAp73 Tumor Suppressor Genes by the Transcription Factor E2F1 Enables Discrimination of Cancer Cells from Normal Growing Cells. *Cells*, 15(1).

Peng M, et al. (2026) In vitro modeling of nutritional and mitochondria-targeted therapies for osteosarcoma. *bioRxiv : the preprint server for biology*.

Dulta K, et al. (2026) To Dye or Not to Dye: Unraveling the Impact of Surface Chemistry on Cerium Oxide Nanoparticles-Cell Interactions. *Small science*, 6(2), e202500446.

Aderhold N, et al. (2026) Combined Inhibition of ATR and Ribonucleotide Reductase Induces Synergistic Antineoplastic Activity in Osteosarcoma Cells. *Cancer reports* (Hoboken, N.J.), 9(5), e70568.

Kostas M, et al. (2026) Unconventional activation of the proto-oncogene FGFR1 by extracellular phosphate via H2O2-mediated kinase oxidation. *Cell reports*, 45(6), 117504.

Güngör Ö, et al. (2026) Triphenylphosphonium-triazole hybrids as mitochondria-targeted anticancer agents: design, DNA binding, cytotoxicity study, fluorescent apoptosis imaging and molecular docking. RSC advances.

Abuetabh Y, et al. (2025) Deciphering UBE4B phosphorylation dynamics: a key mechanism in p53 accumulation and cancer cell response to DNA damage. Cell death discovery, 11(1), 131.

Azeroglu B, et al. (2025) Conserved and unique features of terminal telomeric sequences in ALT-positive cancer cells. eLife, 14.

Gospos J, et al. (2025) Dynamic assessment of a humanized bone tumour microenvironment reveals insights into osteosarcoma primary tumour remodelling and lung metastases. Scientific reports, 15(1), 45619.

Brdar A, et al. (2025) p53 isoforms have a high aggregation propensity, interact with chaperones and lack binding to p53 interaction partners. eLife, 13.

Noh M, et al. (2025) Dimeric R25CPTH(1-34) activates the parathyroid hormone-1 receptor in vitro and stimulates bone formation in osteoporotic female mice. eLife, 13.